837.45 USD
-7.47 (-0.88%)
837.45 USD
0 (0%)
Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 530 industry peers in the Biotechnology industry. While ARGX has a great health rating, its profitability is only average at the moment. ARGX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ARGX suitable for growth investing!
1. Profitability
1.1 Basic Checks
ARGX had positive earnings in the past year.
ARGX had a positive operating cash flow in the past year.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ARGX has a better Return On Assets (17.84%) than 96.23% of its industry peers.
Looking at the Return On Equity, with a value of 21.00%, ARGX belongs to the top of the industry, outperforming 96.23% of the companies in the same industry.
The Return On Invested Capital of ARGX (6.01%) is better than 91.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 6.01% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 41.97%, ARGX belongs to the top of the industry, outperforming 97.36% of the companies in the same industry.
The Operating Margin of ARGX (15.30%) is better than 93.21% of its industry peers.
ARGX has a better Gross Margin (89.40%) than 91.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ARGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
ARGX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 30.33 indicates that ARGX is not in any danger for bankruptcy at the moment.
ARGX's Altman-Z score of 30.33 is amongst the best of the industry. ARGX outperforms 92.83% of its industry peers.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.14, ARGX belongs to the best of the industry, outperforming 95.66% of the companies in the same industry.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ARGX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ARGX outperforms 45.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 30.33 |
ROIC/WACC0.81
WACC7.43%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a Current ratio (5.60) which is comparable to the rest of the industry.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ARGX (5.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 64.71%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 107.34% on average per year.
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.98% yearly.
EPS Next Y935.48%
EPS Next 2Y313.05%
EPS Next 3Y178.04%
EPS Next 5Y107.34%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y34.98%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 62.45, which means the current valuation is very expensive for ARGX.
90.00% of the companies in the same industry are more expensive than ARGX, based on the Price/Earnings ratio.
ARGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.92.
Based on the Price/Forward Earnings ratio of 26.29, the valuation of ARGX can be described as expensive.
Based on the Price/Forward Earnings ratio, ARGX is valued cheaper than 92.83% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.46, ARGX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.45 | ||
| Fwd PE | 26.29 |
4.2 Price Multiples
ARGX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ARGX is cheaper than 89.81% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 91.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 167.02 | ||
| EV/EBITDA | 94.71 |
4.3 Compensation for Growth
ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 178.04% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y313.05%
EPS Next 3Y178.04%
5. Dividend
5.1 Amount
ARGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
837.45
-7.47 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners43%
Inst Owner Change2.31%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap51.56B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts83.2
Price Target972.7 (16.15%)
Short Float %3.02%
Short Ratio5.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14.45%
Revenue beat(16)13
Avg Revenue beat(16)17.87%
PT rev (1m)0.99%
PT rev (3m)13.43%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)-1.69%
EPS NY rev (1m)7.05%
EPS NY rev (3m)15.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)2.97%
Revenue NY rev (3m)6.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.45 | ||
| Fwd PE | 26.29 | ||
| P/S | 16.9 | ||
| P/FCF | 167.02 | ||
| P/OCF | 127.7 | ||
| P/B | 8.46 | ||
| P/tB | 8.77 | ||
| EV/EBITDA | 94.71 |
EPS(TTM)13.41
EY1.6%
EPS(NY)31.85
Fwd EY3.8%
FCF(TTM)5.01
FCFY0.6%
OCF(TTM)6.56
OCFY0.78%
SpS49.55
BVpS99.01
TBVpS95.45
PEG (NY)0.07
PEG (5Y)N/A
Graham Number172.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 6.01% | ||
| ROICexc | 16.72% | ||
| ROICexgc | 18.56% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 30.33 |
F-Score6
WACC7.43%
ROIC/WACC0.81
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y935.48%
EPS Next 2Y313.05%
EPS Next 3Y178.04%
EPS Next 5Y107.34%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y34.98%
EBIT growth 1Y208.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1529.77%
EBIT Next 3Y219.36%
EBIT Next 5Y122.64%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.76%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE - ADR / ARGX FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.
What is the valuation status of ARGENX SE - ADR (ARGX) stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for ARGX stock?
The Earnings per Share (EPS) of ARGENX SE - ADR (ARGX) is expected to grow by 935.48% in the next year.